![Nicolas Poirier](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nicolas Poirier
No open positions remaining
Net worth: 6 M $ as of 2026-05-30
Profile
Nicolas Poirier worked as a Project Manager at Effimune SA. From 2016 to 2026, Dr. Poirier worked at OSE Immunotherapeutics SA, serving as Chief Scientific Officer from 2025 to 2026.
Dr. Poirier completed undergraduate studies at Centre d'Etudes Supérieures de Techniques Industrielles and graduate degrees at the University of Nantes and Louis Pasteur University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2025-09-11 | 1,131,603 ( 4.99% ) | 6 M $ | 2026-05-30 |
Former positions of Nicolas Poirier
| Companies | Position | End |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Chief Executive Officer | 2025-10-01 |
Effimune SA
 Effimune SA BiotechnologyHealth Technology Engages in the research and development of drugs for transplantation and immune-mediated diseases | Corporate Officer/Principal | - |
Training of Nicolas Poirier
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
16
1st degree connections
5
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
University of Nantes
 University of Nantes Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Effimune SA
Effimune SA BiotechnologyHealth Technology Engages in the research and development of drugs for transplantation and immune-mediated diseases | Health Technology |
Centre d'Etudes Supérieures de Techniques Industrielles
 Centre d'Etudes Supérieures de Techniques Industrielles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OSE Immunotherapeutics SA
 OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
Louis Pasteur University
 Louis Pasteur University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
- Stock Market
- Insiders
- Nicolas Poirier
